News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoString Technologies Inc. Secures Option From the Broad Institute for Exclusive Worldwide License of Liver Cancer Gene Signature


4/17/2013 11:22:50 AM

SEATTLE--(BUSINESS WIRE)--NanoString® Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that it has secured an option to an exclusive worldwide license for a 186-gene signature that could be used to determine the prognosis of patients diagnosed with the most common type of liver cancer, hepatocellular carcinoma (HCC), or with hepatitis C-related early-stage cirrhosis. HCC is the third leading cause of cancer mortality worldwide and Hepatitis C cirrhosis-related HCC is the most rapidly increasing cause of cancer related death in the United States.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES